Plain-English translation of NCT06698822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a medication that reduces skin inflammation—can safely and effectively treat early-stage cutaneous T-cell lymphoma, a rare type of blood cancer that appears on the skin. Participants will apply the medication twice daily to up to five affected skin areas and be monitored for 12 weeks (with an option to continue longer) to see if their lesions improve and how well they tolerate the treatment.
Current treatments for early-stage skin lymphoma don't always work well, and some patients' cancer comes back after treatment. Researchers want to see if this medication, which is already used in pill form for other conditions, might offer a safer, more convenient option when applied directly to the skin.
You likely qualify if…
You likely don't qualify if…
You will apply a thin layer of the medication cream to up to five affected skin lesions twice per day at home. You'll visit the clinic at regular intervals (at weeks 4, 8, 12, and beyond if you continue) so researchers can photograph and examine your skin, measure how much itching you experience, and assess your overall well-being. The study lasts at least 12 weeks, with the option to continue treatment for up to one year if you and your doctor agree.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Enrollment target
~20 participants
Started
March 2025
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Julia Dai, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.